Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity

Prostate

Volumn 70, Issue 8, 2010, Pages 883-888

  Algotar, Amit M ^a,b   Thompson, Patricia A ^a,b   Ranger Moore, James ^b   Stratton, M Suzanne ^a   Hsu, Chiu Hsieh ^a,b   Ahmann, Frederick R ^a,c   Nagle, Raymond B ^a,c   Stratton, Steven P ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; NSAID; PSA; PSA velocity; Statin

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM;

ARTICLE; CANCER GROWTH; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; AGED; BLOOD; BODY MASS; DISEASE COURSE; MIDDLE AGED; PROSTATE TUMOR; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK FACTOR; SMOKING;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BODY MASS INDEX; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REGRESSION ANALYSIS; RISK FACTORS; SMOKING;

EID: 77952318028     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21122     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. ACS. Cancer Facts & Figures, 2009. Atlanta: American Cancer Society; 2009.
3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
4. Sutcliffe S, Platz EA. Inflammation in the etiology of prostate cancer: An epidemiologic perspective. Urol Oncol 2007;25:242-249.
5. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002;13:427-434.
6. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-615.
7. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: Systematic review and meta-analysis. Br J Cancer 2004;90:93-99.
8. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-515.
9. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-2225.
10. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98: 1819-1825.
11. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE. Statins and prostate cancer risk: A casecontrol study. Am J Epidemiol 2005;162:318-325.
12. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1108-1111. (Pubitemid 35192666)
13. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005;14:390-396.
14. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: A meta-analysis. JAMA 2006;295:74-80.
15. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH. Cancer risk among statin users: A population-based cohort study. Int J Cancer 2005;114: 643-647. (Pubitemid 40349625)
16. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-2217.
17. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R, Chang SS, Byerly S. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009;181:2064-2070.
18. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: Study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs 2003;14:595-600.
19. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
20. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate E, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Phase 2 clinical trial of selenium in subjects on active surveillance for prostate cancer progression. Cancer Prev Res 2009; (in press).
21. Schroder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol 2009;19:227-231.
22. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-981.
23. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002;167:1723-1726.
24. Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 1999;84:470-474.
25. Neal DEJr, Clejan S, Sarma D, Moon TD. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992;20:105-111.
26. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006;106:1047-1053.